Literature DB >> 25695151

FoxO6 inhibits cell proliferation in lung carcinoma through up-regulation of USP7.

Hong-Jun Hu1, Li-Guo Zhang1, Zhen-Hua Wang1, Xi-Xi Guo1.   

Abstract

Emerging evidence has suggested that misregulation of oncogenes and/or tumor suppressors has a crucial role in the development of lung carcinoma. The present study demonstrated that the expression levels of forkhead box O6 (FOXO6) were downregulated in lung cancer tissue samples, as compared with those in adjacent normal tissue. Overexpression of FOXO6 inhibited the proliferation of A549 human lung cancer cells, whereas knockdown of endogenous FOXO6 expression enhanced cell proliferation. Furthermore, ectopic FOXO6 expression induced the expression of ubiquitin-specific-processing protease 7 (USP7). As a result of this regulation, FOXO6 overexpression led to an elevation of p53 protein expression levels in A549 cells. In conclusion, the results of the present study indicated that the FOXO6/USP7 molecular network has an important role in the regulation of lung cancer development.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25695151     DOI: 10.3892/mmr.2015.3362

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  9 in total

Review 1.  Role of Forkhead Box Class O proteins in cancer progression and metastasis.

Authors:  Chang Geun Kim; Hyemin Lee; Nehal Gupta; Sharavan Ramachandran; Itishree Kaushik; Sangeeta Srivastava; Sung-Hoon Kim; Sanjay K Srivastava
Journal:  Semin Cancer Biol       Date:  2017-08-01       Impact factor: 15.707

Review 2.  Nuclear deubiquitination in the spotlight: the multifaceted nature of USP7 biology in disease.

Authors:  Radhika Rawat; Daniel T Starczynowski; Panagiotis Ntziachristos
Journal:  Curr Opin Cell Biol       Date:  2019-03-18       Impact factor: 8.382

3.  Stabilization of the histone acetyltransferase Tip60 by deubiquitinating enzyme USP7 stimulates the release of pro-inflammatory mediators in acute lung injury.

Authors:  Jing Wang; Hong-Yan Li; Zhen-Bo Su
Journal:  J Mol Med (Berl)       Date:  2020-05-22       Impact factor: 5.606

4.  Downregulation of FOXO6 in breast cancer promotes epithelial-mesenchymal transition and facilitates migration and proliferation of cancer cells.

Authors:  Hui Ye; Meiling Duan
Journal:  Cancer Manag Res       Date:  2018-10-30       Impact factor: 3.989

5.  A Four-Gene Signature Model Improves the Prediction of Distant Metastasis in Patients with Nasopharyngeal Carcinoma: A Retrospective, Three-Center Observational Study.

Authors:  Jinyuan Si; Xiuyong Ding; Zhuoxia Deng; Pu Li; Benjian Zhang; Guiping Lan; Bo Huang; Jinhui Liang; Zhenlin Wang; Yongfeng Si
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

6.  Involvement of the FOXO6 transcriptional factor in breast carcinogenesis.

Authors:  François Lallemand; Ambre Petitalot; Sophie Vacher; Leanne de Koning; Karim Taouis; Bernard S Lopez; Sophie Zinn-Justin; Nicole Dalla-Venezia; Walid Chemlali; Anne Schnitzler; Rosette Lidereau; Ivan Bieche; Sandrine M Caputo
Journal:  Oncotarget       Date:  2017-12-30

7.  USP49 participates in the DNA damage response by forming a positive feedback loop with p53.

Authors:  Rongfu Tu; Wenqian Kang; Xuefei Yang; Qi Zhang; Xiaoyu Xie; Wenbin Liu; Jinxiang Zhang; Xiao-Dong Zhang; Hui Wang; Run-Lei Du
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

8.  Emerging insights into HAUSP (USP7) in physiology, cancer and other diseases.

Authors:  Seemana Bhattacharya; Dipankar Chakraborty; Malini Basu; Mrinal K Ghosh
Journal:  Signal Transduct Target Ther       Date:  2018-06-29

9.  Pharmacokinetic evaluation of the PNC disassembler metarrestin in wild-type and Pdx1-Cre;LSL-KrasG12D/+;Tp53R172H/+ (KPC) mice, a genetically engineered model of pancreatic cancer.

Authors:  Tomas Vilimas; Amy Q Wang; Samarjit Patnaik; Emma A Hughes; Marc D Singleton; Zachary Knotts; Dandan Li; Kevin Frankowski; Jerome J Schlomer; Theresa M Guerin; Stephanie Springer; Catherine Drennan; Christopher Dextras; Chen Wang; Debra Gilbert; Noel Southall; Marc Ferrer; Sui Huang; Serguei Kozlov; Juan Marugan; Xin Xu; Udo Rudloff
Journal:  Cancer Chemother Pharmacol       Date:  2018-10-10       Impact factor: 3.333

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.